MARCH 2019
Defining Value in a Multistakeholder Environment
The market access value proposition for pharmaceutical/biotech products and medical devices requires an approach that is both wide (across organization types) and deep (addressing the needs of multiple stakeholders). These factors drive the need for a multistakeholder value proposition.
Learn More
NOVEMBER 2018
UnitedHealthcare to Apply Step Therapy to Select Medicare Part B Drugs
Utilizing a CMS 2018 policy update, UnitedHealthcare (UHC) is applying step therapy to select Medicare Part B drug classes beginning in 2019. Because UHC plans represent a quarter of the entire Medicare Advantage market, other plan sponsors may follow suit.
Learn More
OCTOBER 2018
Trump’s International Pricing Index Payment (IPI) Model and Pharma
The Trump Administration's proposed international pricing index payment model for Medicare Part B drugs is part of several recent and forthcoming programs designed to follow through on Trump's promise to lower prescription drug prices.
Learn More
SEPTEMBER 2018
Gilead Creates Authorized Generics for Hepatitis C Virus Products Harvoni and Epclusa
Gilead is pursing authorized generics for its hepatitis C virus (HCV) drugs, Harvoni® (ledipasvir/sofosbuvir) and Epclusa® (sofosbuvir/velpatasvir). The creation of authorized generics may become more common if anti-kickback legislation regarding rebates comes to pass.
Learn More
JULY 2018
Improving Diversity and Inclusion in Pharma
Diversity and inclusion have the potential to help the pharmaceutical industry reach larger, more diverse patient populations. Empowering undeserved individuals to take an active role in their health may systematically help to improve population health overall.
Learn More
MAY 2018
The Trump Administration’s Blueprint to Lower Consumer Drug Prices
The Trump Administration’s plan for the United States Department of Health and Human Services may authorize the creation of demonstration projects, waivers, and experiments that may potentially lower drug prices for Medicare beneficiaries.
Learn More
